drugset / Trial / NCT00307814
A Study to Evaluate PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease (PROMPT)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of less frequent dosing of PROCRIT (Epoetin alfa) in patients with anemia due to Chronic Kidney Disease (CKD) as assessed by hemoglobin maintenance, adverse events and health-related quality of life.
Timeline
- Start
- 2002-01
- Primary completion
- —
- Completion
- 2004-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 10000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 20000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 30000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |